We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A new national health study funded by the NH&MRC, industry and state governments released today by the International Diabetes Institute in Melbourne shows diabetes is hitting up to 275 new victims each day throughout Australia.
Response Biomedical Corporation, and Shionogi & Co., Ltd. Announced today the Companies have entered into a Marketing and Supply Agreement to commercialize a rapid quantitative RAMP test in Japan for BNP (B-type natriuretic peptide), a proprietary cardiac marker test to assist in the diagnosis and management of congestive heart failure.
Four new antimalarial drugs are expected to reach sub-Saharan Africa within the next three years, according to the nonprofit Medicines for Malaria Venture (MMV).
Canadians with the gene disorder Fabry disease -- many of whom have no access to drug therapy -- will now be able to obtain two staggeringly expensive medications under a new government deal.
India-based Lupin has entered into an agreement with ItalFarmaco, an Italian pharmaceutical company, to market the cardiovascular critical-care product Lupenox (Enoxaparin sodium injection) in the Indian market.
The World Health Organization (WHO) announced today that 13 pharmaceutical companies have agreed to comply with WHO's recommendation to phase out single-drug artemisinin medicines for oral treatment of malaria.
Beijing Med-Pharm Corporation today announced that it has entered into an agreement with Shanghai CAS Shenglongda Biotech (Group) Co., Ltd. and Shanghai Rongheng International Trade Co. Ltd. of Orient International (Holding) Co. regarding its potential acquisition of a majority interest in Shanghai Rongheng Pharmaceutical Co., Ltd. ("Rongheng"), a pharmaceutical distribution enterprise with operations in Shanghai, China's largest city.